TBS 5

Drug Profile

TBS 5

Alternative Names: Asthma maintenance therapy - Acerus Pharmaceuticals; TBS-5

Latest Information Update: 17 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trimel Pharmaceuticals Corporation
  • Developer Acerus Pharmaceuticals Corporation
  • Class Corticosteroids
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals
  • 04 Mar 2015 Preclinical development is ongoing in Canada
  • 04 Mar 2015 TBS 5 is available for licensing as of 04 Mar 2015. http://trimelpharmaceuticals.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top